Microbiota transplant therapy and autism: lessons for the clinic

James B. Adams, Thomas J. Borody, Dae Wook Kang, Alexander Khoruts, Rosa Krajmalnik-Brown, Michael J. Sadowsky

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (MTT), a type of intensive intestinal microbiota transplantation (IMT), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea). Areas covered: This paper briefly reviews IMT, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive MTT for autism. Expert opinion: An open-label study and a two-year follow-up suggest that MTT is relatively safe and effective in significantly reducing gastrointestinal disorders and autism symptoms, changing the gut microbiome structure, and increasing gut microbial diversity. Further research with larger, randomized, double-blind, placebo-controlled studies is warranted.

Original languageEnglish (US)
Pages (from-to)1033-1037
Number of pages5
JournalExpert Review of Gastroenterology and Hepatology
Issue number11
StatePublished - Nov 2 2019


  • Autism
  • constipation
  • diarrhea
  • fecal microbiota transplant
  • gastrointestinal symptoms
  • intestinal microbiota transplant
  • microbiota transplant therapy
  • vancomycin

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Microbiota transplant therapy and autism: lessons for the clinic'. Together they form a unique fingerprint.

Cite this